NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Shot gene therapy could slash eye injections for wet AMD
Disease control Recruiting nowThis study tests a gene therapy called ABBV-RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can reduce the need for frequent eye injections while keeping vision stable. About 561 adults a…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New eye implant could cut wet AMD treatments to twice a year
Disease control Recruiting nowThis study tests a refillable eye implant (Port Delivery System) that slowly releases the drug ranibizumab to treat wet age-related macular degeneration. The implant is refilled every 36 weeks, potentially reducing the need for frequent eye injections. About 250 participants who …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New eye drug aims to offer cheaper option for blinding disease
Disease control Recruiting nowThis phase 3 trial tests whether a new drug called ABP 938 works as well as the approved treatment Eylea HD for wet age-related macular degeneration, a leading cause of vision loss. About 304 people aged 50 and older with untreated wet AMD will receive injections of either drug i…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New eye injection shows promise for wet AMD in everyday practice
Disease control Recruiting nowThis observational study will follow 300 people with wet age-related macular degeneration (nAMD) who receive aflibercept 8 mg injections as part of their routine care. Researchers want to see how well the drug improves vision and reduces retinal swelling over 12 months, and what …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New eye implant for wet AMD under safety spotlight
Disease control Recruiting nowThis study is testing a refillable eye implant that delivers the drug ranibizumab to treat wet age-related macular degeneration (AMD). The main goal is to see if the implant affects the cells on the inner surface of the cornea. About 188 people with wet AMD will receive the impla…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Eye implant could replace monthly shots for blinding disease
Disease control Recruiting nowThis study tests a small, refillable implant placed in the eye that slowly releases medication for wet age-related macular degeneration (nAMD). It aims to see if refilling the implant every 24 weeks works as well as getting a standard eye injection every 4 weeks. About 68 Chinese…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Eye implant could reduce need for frequent shots for blinding disease
Disease control Recruiting nowThis study is checking the long-term safety of a small implant placed in the eye that slowly releases medicine to treat wet age-related macular degeneration, a condition that can cause rapid vision loss. About 1,000 people who have already used the implant in earlier studies will…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New eye drug aims to clear Vision-Damaging material in wet AMD
Disease control Recruiting nowThis study tests the drug faricimab (Vabysmo) in 100 people aged 50+ with wet age-related macular degeneration who have a specific type of harmful material under their retina. The goal is to see if the drug can clear that material by week 16. Participants receive injections into …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE4 • Sponsor: Biobizkaia Health Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Can a home eye scanner replace frequent doctor visits for wet AMD?
Disease control Recruiting nowThis Phase 3 trial tests whether people with wet age-related macular degeneration can use a home optical coherence tomography (OCT) device to guide when they need eye injections, instead of following a fixed schedule. 600 participants will either receive faricimab injections on a…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New eye drug BBC1501 enters first human safety trial for blinding disease
Disease control Recruiting nowThis early-stage trial tests an experimental drug called BBC1501, given as an injection into the eye, for people with wet age-related macular degeneration (nAMD). The main goal is to check safety and tolerability in 18 volunteers aged 50 and older who have already received standa…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1 • Sponsor: Benobio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New antibody drug trial offers hope for Hard-to-Treat wet AMD
Disease control Recruiting nowThis early-phase trial tests a new drug called PRL3-zumab in 15 people with wet age-related macular degeneration (nAMD) who have not improved with standard treatments. The drug is given by IV every two weeks for three doses. The study will check for safety and any signs that visi…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Gene therapy shot aims to tame wet AMD
Disease control Recruiting nowThis early study tests a single injection of LX111 gene therapy in 10 people aged 50 or older with wet age-related macular degeneration (nAMD). The goal is to see if it is safe and can help control the disease, possibly reducing the need for frequent eye injections. Participants …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New shot for wet AMD aims to save sight
Disease control Recruiting nowThis study tests a new drug called IBI302, given as an eye injection, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can prevent further vision decline over 52 weeks. About 800 adults aged 50 and older with act…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Single shot could replace monthly eye injections for wet AMD
Disease control Recruiting nowThis study tests a new drug called SAR402663, given as a single injection into the eye, for people with wet age-related macular degeneration (AMD). The goal is to see if one dose can safely control the disease and reduce the need for frequent anti-VEGF injections. About 66 partic…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Massive german health data study to map eye disease trends over 15 years
Knowledge-focused Recruiting nowThis study will analyze health records from 2009 to 2024 to find out how many people in Germany have three serious eye conditions: wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Researchers will look at data from two large German health …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Cheaper eye drug could save millions in AMD treatment costs
Knowledge-focused Recruiting nowThis study looks at three drugs (bevacizumab, ranibizumab, and aflibercept) used to treat age-related macular degeneration (AMD), a leading cause of blindness in older adults. Researchers will analyze costs and quality of life for 600 patients in France to see which treatment off…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Eye drug faricimab under the microscope: Real-World data collection begins
Knowledge-focused Recruiting nowThis study is collecting information from 850 people with wet age-related macular degeneration or diabetic macular edema who are being treated with faricimab (VABYSMO) in routine clinical practice. Over two years, researchers will track vision changes, treatment schedules, and sa…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Eye fluid clues may unlock why wet AMD treatment fails for some
Knowledge-focused Recruiting nowThis study aims to find out why 20-40% of people with wet age-related macular degeneration (AMD) don't respond well to standard anti-VEGF injections. Researchers will collect fluid from inside the eye of 117 patients and compare those who respond well to treatment with those who …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: Singapore National Eye Centre • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC